DK0920865T3 - Farmaceutiske sammensætninger indeholdende norastemizol - Google Patents

Farmaceutiske sammensætninger indeholdende norastemizol

Info

Publication number
DK0920865T3
DK0920865T3 DK99200247T DK99200247T DK0920865T3 DK 0920865 T3 DK0920865 T3 DK 0920865T3 DK 99200247 T DK99200247 T DK 99200247T DK 99200247 T DK99200247 T DK 99200247T DK 0920865 T3 DK0920865 T3 DK 0920865T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
compositions containing
compound
formula
treatment
Prior art date
Application number
DK99200247T
Other languages
Danish (da)
English (en)
Inventor
Raymond L Woosley
A K Gunnar Aberg
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK0920865T3 publication Critical patent/DK0920865T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
DK99200247T 1992-09-03 1993-09-03 Farmaceutiske sammensætninger indeholdende norastemizol DK0920865T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94005492A 1992-09-03 1992-09-03

Publications (1)

Publication Number Publication Date
DK0920865T3 true DK0920865T3 (da) 2004-04-19

Family

ID=25474141

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99200247T DK0920865T3 (da) 1992-09-03 1993-09-03 Farmaceutiske sammensætninger indeholdende norastemizol
DK93921359T DK0658110T3 (da) 1992-09-03 1993-09-03 Anvendelse af norastemizol til behandling af allergisk rhinitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK93921359T DK0658110T3 (da) 1992-09-03 1993-09-03 Anvendelse af norastemizol til behandling af allergisk rhinitis

Country Status (13)

Country Link
US (5) US6130233A (pt)
EP (3) EP0920865B1 (pt)
JP (3) JPH08501083A (pt)
AT (2) ATE257704T1 (pt)
AU (1) AU687746B2 (pt)
CA (1) CA2143610C (pt)
DE (3) DE69333387T2 (pt)
DK (2) DK0920865T3 (pt)
ES (2) ES2210957T3 (pt)
GB (1) GB2285219B (pt)
GR (1) GR3032541T3 (pt)
PT (2) PT658110E (pt)
WO (1) WO1994007495A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
NZ517472A (en) * 1997-03-26 2003-08-29 Sepracor Inc Lactose free norastemizole formulations with improved stability
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
BR0210534A (pt) * 2001-06-20 2004-06-22 Schering Corp Anti-histaminas para o tratamento de congestão nasal e obstrução nasal
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
EP2106784B1 (en) * 2008-04-03 2015-04-22 Rohm and Haas Company Hair styling composition
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
CN116194102A (zh) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 用于治疗急性疼痛和降低胃灼热的严重程度和/或风险的包含布洛芬和法莫替丁的单位口服剂量组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
EP0144101B1 (en) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
ES2052544T3 (es) * 1986-02-03 1994-07-16 Janssen Pharmaceutica Nv Composiciones anti-histaminicas que contienen n-heterociclil-4-piperidinaminas.
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
ATE331522T1 (de) 1997-12-23 2006-07-15 Schering Corp Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum

Also Published As

Publication number Publication date
EP0920865A1 (en) 1999-06-09
US6187794B1 (en) 2001-02-13
JP2002308772A (ja) 2002-10-23
DK0658110T3 (da) 2000-04-17
DE69327328D1 (de) 2000-01-20
EP0920865B1 (en) 2004-01-14
AU687746B2 (en) 1998-03-05
EP0658110A1 (en) 1995-06-21
ES2139673T3 (es) 2000-02-16
WO1994007495A1 (en) 1994-04-14
EP1262183A1 (en) 2002-12-04
DE4394931T1 (de) 1995-07-20
PT658110E (pt) 2000-06-30
CA2143610C (en) 2004-08-24
CA2143610A1 (en) 1994-04-14
DE69327328T2 (de) 2000-06-21
US6130233A (en) 2000-10-10
GB2285219B (en) 1996-09-11
GB2285219A (en) 1995-07-05
US6268382B1 (en) 2001-07-31
PT920865E (pt) 2004-06-30
US6124320A (en) 2000-09-26
DE69333387T2 (de) 2004-12-09
ES2210957T3 (es) 2004-07-01
US6187795B1 (en) 2001-02-13
EP0658110B1 (en) 1999-12-15
JPH08501083A (ja) 1996-02-06
GR3032541T3 (en) 2000-05-31
GB9504329D0 (en) 1995-04-26
DE69333387D1 (de) 2004-02-19
AU4848093A (en) 1994-04-26
ATE187642T1 (de) 2000-01-15
ATE257704T1 (de) 2004-01-15
JP2002255817A (ja) 2002-09-11

Similar Documents

Publication Publication Date Title
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
SE9901573D0 (sv) New compounds
TR200101633T2 (tr) Farmasötik bileşim
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
SE9901572D0 (sv) New compounds
DK347289A (da) Terapeutiske forbindelser
BR9808546A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
KR890001555A (ko) 요산 배설용 조성물